EKR Therapeutics is a specialty pharmaceutical company committed to serving the acute-care hospital setting by identifying, commercializing, and marketing products to address unmet or undersatisfied medical needs. Our current product offerings include Ready-to-Use CARDENE^® I.V. (nicardipine hydrochloride), DepoDur^® (morphine sulfate extended-release liposome injection), and Retavase^® (reteplase, recombinant).

We are a respected and active member of the critical care community. Through customized and attentive service to each component of the continuum of care, EKR has become a trusted partner whose knowledge and decision making have earned the respect of hospital administrators and healthcare providers throughout the United States.

Our commitment to providing both needed products and supportive services is playing an important role in enhancing patient care, with a goal of improving outcomes and quality of life.